Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 12/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 2/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21362201 | 0.81 | AHCY (0.50) | AHCYADORA2AADORA1NOS3NOS1 | |
| SCHEMBL15186166 | 0.79 | AHCY (0.51) | AHCYADORA2AADORA1CDK1IKBKB | |
| SCHEMBL2770281 | 0.79 | ADORA2A (0.46) | AHCYADORA2AADORA1CDK1IKBKB | |
| SCHEMBL21372043 | 0.77 | PI4KA (0.51) | AHCYADORA2AADORA1NOS3NOS1 | |
| SCHEMBL4794319 | 0.74 | AHCY (0.40) | AHCYADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL4409861 | 0.74 | PDE4A (0.33) | AHCYADORA2AADORA1 | |
| SCHEMBL4794273 | 0.73 | AHCY (0.39) | AHCYADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL4402905 | 0.73 | ADORA2A (0.39) | ADORA2AADORA1CDK1IKBKBADORA2B | |
| SCHEMBL4790563 | 0.72 | ALDH1A1 (0.39) | AHCYADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL4792327 | 0.72 | AHCY (0.40) | AHCYADORA2AADORA1ADORA2BPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3765474-B1 | CYCLOPENTANE-BASED MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) | PFIZER (US) | 2022-06-15 | — | — | EP | disclosed |
| WO-2019175776-A1 | CYCLOPENTANE-BASED MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) | PFIZER INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| EP-2464651-B1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2016-04-20 | — | — | EP | disclosed |
| US-8933073-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2015-01-13 | — | — | US | disclosed |
| US-8933073-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2015-01-13 | — | — | US | disclosed |
| US-8865662-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8865662-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20140142100-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140142100-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2014-05-22 | — | — | US | disclosed |
| EP-2247294-B1 | MACROLIDES FOR TREATING DISEASES MEDIATED THROUGH PDE INHIBITION | BASILEA PHARMACEUTICA AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-03-03 | — | — | US | disclosed |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-03-03 | — | — | US | disclosed |
| WO-2011018510-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-02-17 | — | — | WO | disclosed |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2011-01-27 | — | — | US | disclosed |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2011-01-27 | — | — | US | disclosed |
| US-20100120706-A1 | Macrolides Useful Against Inflammatory and Allergic Diseases | BASILEA PHARMACEUTICA AG (CH) | 2010-05-13 | — | — | US | disclosed |
| US-20100120706-A1 | Macrolides Useful Against Inflammatory and Allergic Diseases | BASILEA PHARMACEUTICA AG (CH) | 2010-05-13 | — | — | US | disclosed |
| WO-2009106419-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009098320-A2 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2009-08-13 | — | — | WO | disclosed |
| WO-2008017696-A1 | NEW MACROLIDES USEFUL AGAINST INFLAMMATORY AND ALLERGIC DISSEASES | BASILEA PHARMACEUTICA AG (CH) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053876-A1 | MACROLIDES AND THEIR USE | PDE4A, PDE12, PDE4B | AHCY 2152/4885ADORA2A 2894/4885ADORA1 1579/4885 |
| US-20140142100-A1 | NEW MACROLIDES AND THEIR USE | PDE4A, PDE4B, PDE12 | AHCY 1892/4885ADORA2A 2439/4885ADORA1 1343/4885 |
| US-20100120706-A1 | Macrolides Useful Against Inflammatory and Allergic Diseases | HRH4, HRH2, IL4 | AHCY 2761/4885ADORA2A 1843/4885ADORA1 789/4885 |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | MRPS22, MRPS23, MRPL12 | AHCY 2868/4885ADORA2A 3693/4885ADORA1 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.